Human services: medical services; exemption of certain prescription drugs for the treatment or management of pain from the medical assistance prior authorization process; provide for. Amends sec. 109h of 1939 PA 280 (MCL 400.109h) & adds sec. 109v.

Michigan Senate Bill 551, introduced on September 17, 2025, aims to exempt certain prescription drugs used for pain management from the prior authorization process in the state's medical assistance program. Specifically, the bill proposes:

- **Amending Section 109h of 1939 PA 280**: This amendment would prevent the Department of Health and Human Services from requiring prior authorization for certain prescription drugs, including:
- Central nervous system drugs classified as anticonvulsants, antidepressants, antipsychotics, or non-controlled substance antianxiety medications.
- Prescription drugs cross-indicated for these central nervous system drugs.
- Prescription drugs recognized as effective in treating conditions specified in the latest edition of the Diagnostic and Statistical Manual of Mental Disorders, excluding controlled substances and conditions excluded from coverage.

- **Adding Section 109v**: This section mandates that the Department provide coverage under the medical assistance program for non-opioid analgesic drugs prescribed for pain treatment or management. Additionally, within 90 days of the act's effective date, the Department is required to add such drugs to the preferred drug list.

The bill is sponsored by Senators Sylvia Santana and Rosemary Bayer and has been referred to the Senate Health Policy Committee for further consideration. ([legiscan.com](https://legiscan.com/MI/bill/SB0551/2025?utm_source=openai))

While specific media coverage on Michigan Senate Bill 551 is limited, the bill's focus on streamlining access to pain management medications without prior authorization is likely to be viewed positively by healthcare providers and patients. By reducing bureaucratic hurdles, the bill aims to ensure timely access to necessary treatments, potentially improving patient outcomes and satisfaction. The inclusion of non-opioid analgesics in the preferred drug list aligns with ongoing efforts to promote safer pain management alternatives, which may be welcomed by public health advocates.

Although direct media reactions to Michigan Senate Bill 551 are scarce, some stakeholders might express concerns about the bill's potential impact on prescription drug costs. Pharmaceutical companies and insurers could be apprehensive about the financial implications of expanding coverage for additional medications. Additionally, there may be apprehension regarding the bill's potential to inadvertently increase the use of certain medications, leading to concerns about overprescription or misuse. However, without specific media coverage, these considerations remain speculative.